PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 21, 2012--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has
been selected for inclusion in the NASDAQ Biotechnology Index® (NASDAQ:
NBI) effective today. The National Biotechnology Index is designed to
track the performance of biotechnology or pharmaceutical companies
listed exclusively on the NASDAQ Global Select Market or on the NASDAQ
Global Market that meet eligibility criteria including a minimum market
capitalization of $200 million and a minimum daily trading volume of
100,000 shares, amongst other requirements.
The index is ranked semi-annually in May and November and serves as the
basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq:IBB). In
addition, options based on the NASDAQ Biotechnology Index and the
iShares Nasdaq Biotechnology Index Fund trade on various exchanges. For
more information about the NBI, including eligibility criteria, visit https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company's current emphasis is the
development of non-opioid products for postsurgical pain control, and
its lead product, EXPAREL® (bupivacaine liposome injectable suspension),
was commercially launched in the United States in April 2012. EXPAREL
and two other commercially available products utilize the Pacira
proprietary product delivery technology DepoFoam®, a unique platform
that encapsulates drugs without altering their molecular structure and
then releases them over a desired period of time. Additional information
about Pacira is available at www.pacira.com.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
